Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism

Australian Veterinary Journal

Volumn 81, Issue 10, 2003, Pages 600-607

  Braddock, J A ^a   Church, D B ^b   Robertson, I D ^c   Watson, A D J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

^c MURDOCH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS;

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANDROSTANOLONE; DRUG DERIVATIVE; ENZYME INHIBITOR; HYDROCORTISONE; TRILOSTANE;

ADRENAL CORTEX HYPERFUNCTION; ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CLINICAL TRIAL; DOG; DOG DISEASE; DRUG ADMINISTRATION; DRUG ANTAGONISM; FEMALE; MALE; PATHOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

3-HYDROXYSTEROID DEHYDROGENASES; ADRENOCORTICAL HYPERFUNCTION; ANIMALS; DIHYDROTESTOSTERONE; DOG DISEASES; DOGS; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HYDROCORTISONE; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 2342467406     PISSN: 00050423     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1751-0813.2003.tb12498.x     Document Type: Article

References (32)

1. Hurley K, Sturgess K, Cauvin A, Kuipers R. The use of trilostane for the treatment of hyperadrenocorticism in dogs [abstract]. J Vet Intern Med 1998;12:210.
2. Potts GO, Creange JE, Harding HR, Schane HP. Trilostane, an orally active inhibitor of steroid biosynthesis. Steroids 1978;32:257-267.
3. Dewis P, Anderson DC, Bu'lock DE, Earnshaw R, Kelly WF. Experience with trilostane in the treatment of Cushing's syndrome. Clin Endocrinol 1983;18:533-540.
4. Semple CG, Beastall GH, Gray CE, Thomson JA. Trilostane in the management of Cushing's syndrome. Acta Endocrinol 1983;102:107-110.
5. Engelhardt D. Steroid biosynthesis inhibitors in Cushing's syndrome. Clin Investig 1994;72:481-488.
6. Engelhardt D, Weber MM. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Molec Biol 1994;49:261-267.
7. Komanicky P, Spark RF, Melby JC. Treatment of Cushing's disease with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. J Clin Endocrinol 1978;47:1042-1051.
8. Dorrington-Ward P, Carter G, Banks R, MacGregor G. Trilostane as a cause of Addisonian crisis [letter]. Lancet 1981;2:1178.
9. Williams CJ, Barley VL, Blackledge GR, Rowland CG, Tyrell CJ. Multicentre cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer. Br J Cancer 1993;68:1210-1215.
10. Geldof AA, Dijkstra I, Newling DWW, Rao BR. Inhibition of 3β-hydroxysteroid-dehydrogenase: an approach for prostate cancer treatment? Anticancer Res 1995;15:1349-1354.
11. Shigetomi S, Fukuchi S, Haruyama K, Yamazaki M. The effect of trilostane, a new inhibitor of adrenal steroid biosynthesis, on blood pressure, plasma aldosterone and other steroid hormones, serum potassium and plasma renin activity in primary aldosteronism. Folia Endocrinol Jap 1982;58:184-198.
12. Nakada T, Kazama T, Koike H et al. Primary aldosteronism treated by trilostane (3β-hydroxysteroid dehydrogenase inhibitor). Urology 1985;25:207-214.
13. Nomura K, Demura H, Horiba N, Shizume K. Long-term treatment of idiopathic hyperaldosteronism using trilostane. Acta Endocrinol 1986;113:104-110.
14. Griffing GT, Melby JC. Reversal of diuretic-induced secondary hyperaldosteronism and hypokalaemia by trilostane, an inhibitor of adrenal steroidogenesis. Metabolism 1989;38:353-356.
15. 5-isomerase [abstract]. Program of the 57th Annual Meeting of The Endocrine Society, New York, June 18-20, 1975:abstract 15.
16. Ramsey IK, Hurley K. Use of trilostane in hyperadrenocorticism [abstract]. J Small Anim Pract 2000;41:373.
17. Neiger R, Hurley K. 24-hour cortisol values in dogs with hyperadrenocorticism on trilostane [abstract]. J Small Anim Pract 2001;42:376.
18. Neiger R, Ramsey IK. Trilostane therapy of canine hyperadrenocorticism. Proc 20th Annual Medical Forum Am Coll Vet Intern Med, Dallas, 2002;544-546.
19. Neiger R, Ramsey I, O'Connor J, Hurley KJ, Mooney CT. Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 2002;150:799-804
20. Ruckstuhl NS, Reusch CE. Results of clinical examinations, laboratory tests and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Am J Vet Res 2002;63:506-512.
21. McGowan CM, Neiger R. Efficacy of trilostane in the management of equine Cushing's disease [abstract]. J Vet Intern Med 2001;15:322.
22. Feldman EC, Nelson RW. Hyperadrenocorticism (Cushing's syndrome). In: Canine and Feline Endocrinology and Reproduction, 2nd edn. Saunders, Philadelphia, 1996:187-265.
23. Watson ADJ, Church DB, Emslie DR, Foster SF. Plasma cortisol responses to three corticotrophic preparations in normal dogs. Aust Vet J 1998;76:255-257.
24. Watson ADJ, Church DB, Emslie DR. Plasma cortisol concentrations in dogs given cortisone or placebo by mouth. Res Vet Sci 1993;55:379-381.
25. Smiley LE, Peterson ME. Evaluation of a urine cortisol:creatinine ratio as a screening test for hyperadrenocorticism in dogs. J Vet Intern Med 1993;7:163-168.
26. Hegstad RL, Johnston SD, Pasternak DM. Effects of sample handling on adrenocorticotropin concentration measured in canine plasma, using a commercially available radioimmunoassay kit. Am J Vet Res 1990;51:1941-1947.
27. Braddock JA. Investigation of some alternative therapies for management of pituitary-dependent hyperadrenocorticism in the dog. Masters thesis, The University of Sydney. 2002.
28. Mattingly D, Tyler C. Trilostane interference with fluorimetric steroid assays [letter]. Lancet 1981;i:561.
29. Robinson DT, Earnshaw RJ, Mitchell R et al. The bioavailability and metabolism of trilostane in normal subjects, a comparative study using high pressure liquid chromatographic and quantitative cytochemical assays. J Steroid Biochem 1984;21:601-605.
30. McGee JP, Palin KJ, Shaw PN, Potter C. High performance liquid chromatographic analysis of trilostane and ketotrilostane in rat plasma. J Chromat Biomed Applic 1991;567:282-287.
31. Mori Y, Tsuboi M, Suzuki M, Saito A, Ohnishi H. Studies on the metabolism of trilostane, an inhibitor of adrenal steroidogenesis. Chem Pharmac Bull 1981;29:2646-2652.
32. Nelson RW, Feldman EC, Shinsako J. Effect of o,p'-DDD therapy on endogenous ACTH concentrations in dogs with hypophysis-dependent hyperadrenocorticism. Am J Vet Res 1985;46:1534-1537.